In advanced-stage solid cancer patients, popular targeted therapies such as kinase inhibitors against ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), RET (ret proto-oncogene), ROS1 (ROS proto-oncogene 1), and MEK (mitogen-activated protein kinase 1) lead to the progression of a therapy-resistant tumor after an inadequate therapeutic response [1]. Here, ALK is linked to neoplasm.